Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline

Biochemical and Biophysical Research Communications

Volumn 410, Issue 2, 2011, Pages 229-234

  Wang, Dong ^a   Yang, Liguo ^a   Su, Jingjing ^a   Niu, Yan ^b   Lei, Xiaoping ^b   Xiong, Juan ^c   Cao, Xiaohua ^a   Hu, Yinghe ^a   Mei, Bing ^a   Hu, Jin Feng ^a,c  

^a B326 Science Building   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; EUK1001; Muscarinic M1 agonist; Neurodegeneration; Presenilins; Xanomeline

Indexed keywords

EUK 1001; MUSCARINIC M1 RECEPTOR AGONIST; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOLOGY; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECOGNITION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; MUSCARINIC AGONISTS; NERVE TISSUE PROTEINS; PHOSPHORYLATION; PRESENILIN-1; PRESENILIN-2; PYRIDINES; TAU PROTEINS; THIADIAZOLES;

MUS;

EID: 79959712000     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.120     Document Type: Article

References (29)

1. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403.
2. Musial A., Bajda M., Malawska B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr. Med. Chem. 2007, 14:2654-2679.
3. Nordberg A., Alafuzoff I., Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 1992, 31:103-111.
4. Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., LaFerla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49:671-682.
5. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update. Curr. Alzheimer. Res. 2007, 4:577-580.
6. Bodick N.C., Offen W.W., Levey A.I., Cutler N.R., Gauthier S.G., Satlin A., Shannon H.E., Tollefson G.D., Rasmussen K., Bymaster F.P., Hurley D.J., Potter W.Z., Paul S.M. Effects of xanomeline, a selective muscarinic receptor agonist on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 1997, 54:465-473.
7. Bodick N.C., Offen W.W., Shannon H.E., Satterwhite J., Lucas R., van Lier R., Paul S.M. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer. Dis. Assoc. Disord. 1997, 11 Suppl 4:S16-22.
8. Cui Y., Wang D., Si W., Lv W., Niu Y., Lei X., Hu Y., Cao X. Enhancement of memory function in aged mice by a novel derivative of xanomeline. Cell Res. 2008, 18:1151-1153.
9. Si W., Zhang X., Niu Y., Yu H., Lei X., Chen H., Cao X. A novel derivative of xanomeline improves fear cognition in aged mice. Neurosci. Lett. 2010, 473:115-119.
10. Hutton M., Hardy J. The presenilins and Alzheimer's disease. Hum. Mol. Genet. 1997, 6:1639-1646.
11. Saura C.A., Choi S.Y., Beglopoulos V., Malkani S., Zhang D., Shankaranarayana Rao B.S., Chattarji S., Kelleher R.J., Kandel E.R., Duff K., Kirkwood A., Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004, 42:23-36.
12. Feng R., Wang H., Wang J., Shrom D., Zeng X., Tsien J.Z. Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2. Proc. Nat. Acad. Sci. USA 2004, 101:8162-8167.
13. Jiang X., Zhang D., Shi J., Chen Y., Zhang P., Mei B. Increased inflammatory response both in brain and in periphery in presenilin 1 and presenilin 2 conditional double knock-out mice. J. Alzheimers. Dis. 2009, 18:515-523.
14. Beglopoulos V., Sun X., Saura C.A., Lemere C.A., Kim R.D., Shen J. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J. Biol. Chem. 2004, 279:46907-46914.
15. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
16. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhuo M., Liu G., Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature 1999, 401:63-69.
17. Rampon C., Tang Y.P., Goodhouse J., Shimizu E., Kyin M., Tsien J.Z. Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat. Neurosci. 2000, 3:238-244.
18. Wu P., Shen Q., Dong S., Xu Z., Tsien J.Z., Hu Y. Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and presenilin-2 double knockout mice. Neurobiol. Aging 2008, 29:1502-1511.
19. Dong S., Li C., Wu P., Tsien J.Z., Hu Y. Environment enrichment rescues the neurodegenerative phenotypes in presenilins-deficient mice. Eur. J. Neurosci. 2007, 26:101-112.
20. Han W., Ji T., Wang L., Yan L., Wang H., Luo Z., Mei B., Su J. Abnormalities in periodontal and salivary tissues in conditional presenilin 1 and presenilin 2 double knockout mice. Mol. Cell. Biochem. 2010, 347:13-20.
21. Razani-Boroujerdi S., Behl M., Hahn F.F., Pena-Philippides J.C., Hutt J., Sopori M.L. Role of muscarinic receptors in the regulation of immune and inflammatory responses. J. Neuroimmunol. 2008, 194:83-88.
22. Sales M.E. Muscarinic receptors as targets for anti-inflammatory therapy. Curr. Opin. Invest. Drugs 2010, 11:1239-1245.
23. Conn P.J., Christopoulos A., Lindsley C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discovery 2009, 8:41-54.
24. Jones C.K., Brady A.E., Davis A.A., Xiang Z., Bubser M., Tantawy M.N., Kane A.S., Bridges T.M., Kennedy J.P., Bradley S.R., Peterson T.E., Ansari M.S., Baldwin R.M., Kessler R.M., Deutch A.Y., Lah J.J., Levey A.I., Lindsley C.W., Conn P.J. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008, 28:10422-10433.
25. Langmead C.J., Austin N.E., Branch C.L., Brown J.T., Buchanan K.A., Davies C.H., Forbes I.T., Fry V.A., Hagan J.J., Herdon H.J., Jones G.A., Jeggo R., Kew J.N., Mazzali A., Melarange R., Patel N., Pardoe J., Randall A.D., Roberts C., Roopun A., Starr K.R., Teriakidis A., Wood M.D., Whittington M., Wu Z., Watson J. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 2008, 154:1104-1115.
26. Sams A.G., Hentzer M., Mikkelsen G.K., Larsen K., Bundgaard C., Plath N., Christoffersen C.T., Bang-Andersen B. Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. J. Med. Chem. 2010, 53:6386-6397.
27. Caccamo A., Fisher A., LaFerla F.M. M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr. Alzheimer. Res. 2009, 6:112-117.
28. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
29. Mirza N.R., Peters D., Sparks R.G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003, 9:159-186.